Role of biologics in intractable urticaria

Andrew Cooke,1 Adeeb Bulkhi,1,2 Thomas B Casale1 1Department of Internal Medicine, Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA; 2Department of Internal Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia Abstract: Chronic urticaria (CU) i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cooke A, Bulkhi A, Casale TB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1f5e328b780047d1a7fdab4661d94713
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1f5e328b780047d1a7fdab4661d94713
record_format	dspace
spelling	oai:doaj.org-article:1f5e328b780047d1a7fdab4661d947132021-12-02T02:45:40ZRole of biologics in intractable urticaria1177-5491https://doaj.org/article/1f5e328b780047d1a7fdab4661d947132015-04-01T00:00:00Zhttp://www.dovepress.com/role-of-biologics-in-intractable-urticaria-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491 Andrew Cooke,1 Adeeb Bulkhi,1,2 Thomas B Casale1 1Department of Internal Medicine, Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA; 2Department of Internal Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia Abstract: Chronic urticaria (CU) is a common condition faced by many clinicians. CU has been estimated to affect approximately 0.5%–1% of the population, with nearly 20% of sufferers remaining symptomatic 20 years after onset. Antihistamines are the first-line therapy for CU. Unfortunately, nearly half of these patients will fail this first-line therapy and require other medication, including immune response modifiers or biologics. Recent advances in our understanding of urticarial disorders have led to more targeted therapeutic options for CU and other urticarial diseases. The specific biologic agents most investigated for antihistamine-refractory CU are omalizumab, rituximab, and intravenous immunoglobulin (IVIG). Of these, the anti-IgE monoclonal antibody omalizumab is the best studied, and has recently been approved for the management of CU. Other agents, such as interleukin-1 inhibitors, have proved beneficial for Schnitzler syndrome and cryopyrin-associated periodic syndromes (CAPS), diseases associated with urticaria. This review summarizes the relevant data regarding the efficacy of biologics in antihistamine-refractory CU. Keywords: chronic urticaria, omalizumab, intravenous immunoglobulin, anakinra, canakinumabCooke ABulkhi ACasale TBDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 25-33 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Cooke A Bulkhi A Casale TB Role of biologics in intractable urticaria
description	Andrew Cooke,1 Adeeb Bulkhi,1,2 Thomas B Casale1 1Department of Internal Medicine, Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA; 2Department of Internal Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia Abstract: Chronic urticaria (CU) is a common condition faced by many clinicians. CU has been estimated to affect approximately 0.5%–1% of the population, with nearly 20% of sufferers remaining symptomatic 20 years after onset. Antihistamines are the first-line therapy for CU. Unfortunately, nearly half of these patients will fail this first-line therapy and require other medication, including immune response modifiers or biologics. Recent advances in our understanding of urticarial disorders have led to more targeted therapeutic options for CU and other urticarial diseases. The specific biologic agents most investigated for antihistamine-refractory CU are omalizumab, rituximab, and intravenous immunoglobulin (IVIG). Of these, the anti-IgE monoclonal antibody omalizumab is the best studied, and has recently been approved for the management of CU. Other agents, such as interleukin-1 inhibitors, have proved beneficial for Schnitzler syndrome and cryopyrin-associated periodic syndromes (CAPS), diseases associated with urticaria. This review summarizes the relevant data regarding the efficacy of biologics in antihistamine-refractory CU. Keywords: chronic urticaria, omalizumab, intravenous immunoglobulin, anakinra, canakinumab
format	article
author	Cooke A Bulkhi A Casale TB
author_facet	Cooke A Bulkhi A Casale TB
author_sort	Cooke A
title	Role of biologics in intractable urticaria
title_short	Role of biologics in intractable urticaria
title_full	Role of biologics in intractable urticaria
title_fullStr	Role of biologics in intractable urticaria
title_full_unstemmed	Role of biologics in intractable urticaria
title_sort	role of biologics in intractable urticaria
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/1f5e328b780047d1a7fdab4661d94713
work_keys_str_mv	AT cookea roleofbiologicsinintractableurticaria AT bulkhia roleofbiologicsinintractableurticaria AT casaletb roleofbiologicsinintractableurticaria
_version_	1718402148558962688

Role of biologics in intractable urticaria

Ejemplares similares